title: Allogeneic hematopoietic stem cell transplant for hematological malignancies from mismatched 9/10 human leukocyte antigen unrelated donors: comparison with transplants from 10/10 unrelated donors and human leukocyte antigen identical siblings.
abstract: We studied the outcome of 213 patients who received allo-HSCT for hematological malignancies, 121 (57%) from HLA identical siblings, 63 (29%) from 10/10 HLA identical unrelated donors and 29 (14%) from 9/10 HLA mismatched unrelated donors. Engraftment was lower in the 9/10 HLA group (90%) than in the 10/10 HLA group (95%) than in the sibling group (99%); 3 months CI of aGVHD ≥ 2 was 32% (23-41), 20% (15-26) and 27% (23-32) respectively; the one year CI of extensive cGVHD was 21% (13-30), 9% (5-13) and 17% (14-21) respectively. The median OS was 10 months (5-21), 18 months (11-NR) and 60 months (31-NR) respectively with 2-years probability of 19% (8-44), 43% (31-59) and 63% (54-74) respectively. TRM was significantly higher in the 9/10 HLA group with 1 year CI of 45% (35-55), compared to 33% (27-39) in the unrelated 10/10 HLA group and 12% (9-15) in the identical siblings group (p < 0.001).
authors.affiliation: Hospices Civils de Lyon, Blood and Marrow Transplant Unit, Department of Hematology 1G, Centre Hospitalier Lyon Sud , Pierre Benite , France.
authors.forename: Mauricette
authors.initials: M
authors.lastname: Michallet
authors.forename: Mohamad
authors.initials: M
authors.lastname: Sobh
authors.forename: Caroline
authors.initials: C
authors.lastname: Serrier
authors.forename: Stéphane
authors.initials: S
authors.lastname: Morisset
authors.forename: Hélène
authors.initials: H
authors.lastname: Labussière
authors.forename: Sophie
authors.initials: S
authors.lastname: Ducastelle
authors.forename: Fiorenza
authors.initials: F
authors.lastname: Barraco
authors.forename: Lila
authors.initials: L
authors.lastname: Gilis
authors.forename: Xavier
authors.initials: X
authors.lastname: Thomas
authors.forename: Franck E
authors.initials: FE
authors.lastname: Nicolini
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology / Q000276:immunology; D006680:HLA Antigens / Q000276:immunology*; D019337:Hematologic Neoplasms / Q000276:immunology* / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000706:statistics & numerical data; D012008:Recurrence; D035781:Siblings; D016019:Survival Analysis; D014184:Transplantation, Homologous; D061349:Unrelated Donors; D055815:Young Adult
chemical_list: D006680:HLA Antigens
keywords: 10/10 HLA; 9/10 HLA; Unrelated donors; identical siblings